| INTRODUCTION
A very high efficacy of sofosbuvir-based direct-acting antiviral regimens is observed in liver transplant recipients with viral C hepatitis (HCV) recurrence, whatever the grade of fibrosis. 1 As a matter of concern, sofosbuvir-based regimens are associated with changes in renal function between treatment onset, end of treatment (EOT) and/or end of follow-up. [1] [2] [3] [4] [5] [6] [7] It is not clear whether these modifications are a sign of renal toxicity or not. Serum creatinine and the estimated glomerular filtration rate (eGFR) are widely used to appreciate changes in renal function over time but have limitations. In fact, the glomerular filtration rate (GFR) is highly variable. The true GFR, measured with an exogenous filtration marker, has a between day intra-individual coefficient of variation of 12%-17% 8 and depends on the level of hydration. 9 Autoregulation of the renal blood flow, which accounts for a constant GFR, is compromised in diabetes, in patients treated with the calcineurin inhibitor or treated for high blood pressure. [10] [11] [12] [13] Therefore, the results from studies using a 2-point determination of serum creatinine or eGFR to assess renal safety of sofosbuvir-based regimens should be interpreted with caution. Actually, a reference level of eGFR is hardly given by a single assay of serum creatinine, 14 but changes in the eGFR under treatment depend on the previous renal function trajectory. 15, 16 Several serum creatinine levels are able to limit the effect of intrinsic variations in eGFR. 14 Classically, assessment of the trajectory of renal function from the slope of the eGFR is recommended to study the effect of any treatment on the kidneys. 14, 17 In the present study, performed from a large multi-centric cohort of liver transplant recipients with HCV recurrence, we used 2 approaches. First, we considered trajectories of the eGFR over 3 periods, namely pre-treatment, ontreatment and post-treatment periods. 1 Second, we considered trajectories of the renal function during the short period of treatment as usually done. Then, we confronted the results of these 2 approaches to shed light on the real effect of sofosbuvir-based regimens on the kidneys.
| PATIENTS AND METHODS
The ANRS CO23 CUPILT study, sponsored and funded by Inserm-ANRS, was conducted in 25 French and Belgium liver transplant centres (ClinicalTrials.gov number NCT01944527). To be included in the cohort, patients had to be transplanted, presented with allograft HCV recurrence, and treated with second-generation direct acting antiviral agents. The main criteria for exclusion were age less than 18 years and pregnancy. From October 2013 to December 2015, 699 patients with HCV recurrence were included in the cohort.
| Study design
Patients treated with a sofosbuvir-based regimen and for whom values of serum creatinine were available before, under and after the sofosbuvir-based treatment were enrolled. The stage of fibrosis on enrolment was established based on histological assessment (according to the METAVIR scoring system) and/or on liver elastometry (such as F3 ≥ 9.5 kPa and F4 ≥ 14.5 kPa). Antiviral treatment could also contain a NS5A inhibitor and/or ribavirin. Treatment regimens were at the discretion of investigators. In most patients, the planned duration of treatment was 12 or 24 weeks. Exclusion criteria from the present analysis were patients with double or multiple organ transplantations, patients on haemodialysis before direct acting antiviral agents treatment, HIV infection and fibrosing cholestatic hepatitis (Figure 1 ). The protocol was conducted in accordance with the Declaration of Helsinki and French law for biomedical research and was approved by the "Sud M editerran ee" Ethics Committee (France). Written informed consent was obtained from each patient before enrolment.
| Renal assessment
Retrospective collection of serum creatinine levels at 12, 6 and 3 months (M) before direct acting antiviral agents initiation was performed. Prospective serum creatinine levels were collected and monitored at day 0 (beginning of the direct-acting antiviral agents treatment), day 7 after treatment onset, at the EOT, at EOT + 3 months and at EOT + 6 months. The CKD-EPI equation was used to calculate the eGFR. 18 Two determinations of serum 
| Statistics
Statistical analyses were performed using SAS statistical software (SAS Institute, Cary, NC, USA) and R 3. 
| Characteristics of the patients
One hundred and thirty-nine patients (77% men) aged 58 (IQR 53-65) years were included in this study ( Figure 1) . Diabetes was present in 51 patients (37%) and hypertension in 71 (51%). Eighty-four patients (60%) were on tacrolimus, while the others were on ciclosporin (29%) or everolimus (7%) ( Table 1) . Eighty-one patients had F3 or F4 stage, including 47 cirrhotic patients (34%). The severity of cirrhosis was
Child-Pugh A in 26 patients (63%), Child-Pugh B in 14 patients (34%)
and Child-Pugh C in 1 patient. The median Child-Pugh score was 6
(IQR 5-7) [5] [6] [7] [8] [9] [10] [11] and the median MELD score was 10 (IQR 8-13) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
The different regimens of direct-acting antiviral agents were sofosbuvir+daclatasvir (55%), sofosbuvir+daclatasvir+ribavirin (30%) or sofosbuvir+ribavirin (14%). The total observation time was 16.5-22.5 months, depending on the duration of the on-treatment period, ranging from 3 to 9 months ( | 1685 and one-third had a median on-treatment slope of +0.75 (IQR +0.28
to +1.47) mL/min/1.73 m 2 /month. For each tertile, there was no statistically significant difference in the pre-treatment slope as compared with the post-treatment slope (Table 3) .
| No influence of pre-treatment eGFR
According to the eGFR M-9 (pre-treatment eGFR), 92 patients (66%)
were above 60 mL/min/ . There was no global interaction between the pre-treatment eGFR and eGFR slopes during the 3 periods, namely pre-treatment, on-treatment and post-treatment periods (P = 0.99).
Details are given in Table 4 .
| No influence of ribavirin use
There was a global interaction between ribavirin and eGFR slopes during the pre-treatment, on-treatment and post-treatment periods (P = 0.004) but no deleterious impact of ribavirin on renal function.
Actually, the pre-treatment eGFR slope was lower (À0. 
| No influence of the stage of fibrosis

| DISCUSSION
We first observed that the eGFR slope increased globally over the total observation time of 16.5-22.5 months, including the on-treatment period (Figure 3 ), meaning that sofosbuvir-based regimens are not toxic for the kidneys in this cohort. We then observed that the eGFR slope might drop, remain stable or rise during the on-treatment period. This demonstrated that conclusions drawn from eGFR variations over a short period of time might be misleading due to methodological bias. Short-time eGFR variability is well known and related to physiological changes of true GFR. 8, 9 GFR may change following the hydration level. 9 Several comorbid conditions may compromise autoregulation of the renal blood flow, depending on a and increase in the eGFR. 13 During this study, the management of the calcineurin inhibitors and other medical treatments was done according to the investigator's discretion. The increase in the eGFR might reflect an improvement in kidney function 27 or a loss of muscle mass, this latter hypothesis being unlikely because of the good overall outcome of the patients. 28 A decrease in eGFR might result from prerenal azotemia following hepatic decompensation, as suggested by Butt et al. 29 However, we found no deleterious impact of the stage of fibrosis on the eGFR slope, meaning that cirrhosis was not associated with an eGFR decrease during the observation of our cohort. Similarly, we did not find any influence of mycophenolate mofetil or ribavirin use on eGFR slopes during sofosbuvir-based regimens, even though ribavirin is less and less used with current regimens.
30,31
The limitations of our study are linked to the use of serum creatinine to estimate GFR. The serum creatinine level is subjected to inconsistencies that depend on the method of assay, on dietary variations and on drug-dependent tubular elimination. 14 In this study, the transient use of drugs potentially implicated in the decrease in tubular creatinine secretion cannot be rule out. Moreover, other markers of renal insult were not available, as for example urinary albumin or tubular markers such as neutrophil gelatinase-associated lipocalin or kidney injury molecule-1. We did not measure lean body mass to assess whether serum creatinine changed with body composition. Further, we are aware that differences exist between estimated and measured GFR in cross-sectional and in longitudinal studies. 32 However, estimation of GFR with serum creatinine remains the most commonly used approach and our results are based on a prospective and large cohort with a long duration of follow-up. Finally, the precision of the eGFR formula may be questioned in patients with normal or mild impaired renal function, as for 66% of the patients in our cohort. 33 To overcome this limitation, we used the mean of 2 serum creatinine assays to calculate every eGFR.
In conclusion, we show that the eGFR determined with a 2-point method in liver transplant recipients may rise, remain stable or fall during treatment with sofosbuvir-based regimens and in the latter case, may mimic renal toxicity. However, we suggest that long-term longitudinal observations and several levels of serum creatinine should be considered to draw conclusions on the renal toxicity of sofosbuvir-based regimens, which were harmless for the kidney function in our cohort of liver transplant recipients with HCV recurrence.
T A B L E 3 Repartition of patients in tertiles according to the on-treatment slope eGFR slopes 1st tertile (n = 46) 2nd tertile (n = 47) 3rd tertile (n = 46) Patients were separated according to their pre-treatment eGFR. Values are medians (interquartile ranges). eGFR, estimated glomerular filtration rate. There was no global interaction between the pre-treatment eGFR and periods of slopes (P = 0.99).
